Skip to content
Open access

Systems genetics approaches model the heritable architecture of polyendocrine metabolic ovarian syndrome.

Aug 2026 · Journal of Clinical Investigation · 0 citations
Medicine

TL;DR

It is shown that increased ovarian area contributes to both PMOS susceptibility and ovarian cancer progression, while specific ovary-heart signaling circuits modulate cardiac function with aging, and SF3B1-mediated splicing is uncovered as a link between ovary function and systemic metabolism.

Abstract

Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is the most common endocrine disorder in women and is closely associated with complex diseases such as cardiovascular disease and type 2 diabetes. However, the mechanistic links between PMOS and its comorbidities remain poorly understood. Here, we present an integrative systems genetics platform that leverages genetic diversity in both mice and humans to dissect the drivers of PMOS and its associated complications. This framework uncovers conserved genetic and environmental factors underlying PMOS, identifies susceptible cell types and organs, and elucidates mechanisms linking PMOS to subsequent pathologies. For instance, we show that increased ovarian area contributes to both PMOS susceptibility and ovarian cancer progression, while specific ovary-heart signaling circuits modulate cardiac function with aging. We further identify ovarian SF3B1-mediated alternative splicing as a key mechanistic link between PMOS and metabolic traits. Pharmacologic inhibition of SF3B1 in mice reduced circulating testosterone, insulin and glucose levels, as well as fat mass expansion. Transcriptomics analysis of ovaries from mice and experiments using human cell lines localized these effects to exon skipping events in granulosa cells. Together, this study offers a mechanistic framework for modeling the diversity of PMOS pathologies and uncovers SF3B1-mediated splicing as a link between ovary function and systemic metabolism.

Read PDF

Similar papers

Review Open access Aug 2026

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk

Recognizing PMOS as an early-life marker of cardiometabolic disease highlights opportunities for earlier diagnosis, prevention, and individualized risk stratification, supporting integrated, patient-centered care across the life course.

M. Forslund, J. Melin, A. Joham et al. · 0 citations
Review Jul 2026

Polycystic ovary syndrome and insulin resistance: A focus on pathogenesis, risk factors, and therapeutic strategies.

A comprehensive and personalized therapeutic approach integrating pharmacological, lifestyle, and microbiome-targeted interventions may significantly improve PCOS management and reduce long-term metabolic and reproductive complications.

J. Singla, Shubhi Yadav, J. Gayen · 0 citations
Review Jul 2026

Steroidogenic Enzyme Dysregulation in Polycystic Ovary Syndrome: Mechanistic Insights and Emerging Therapeutic Strategies.

Understanding enzyme-level dysregulation offers opportunities for mechanism-based interventions that can restore steroidogenic homeostasis, improve fertility outcomes, and mitigate long-term metabolic risk in PCOS.

Thirumurugan Ayyadurai, S. Ravi, Aravinth Annamalai · 1 citation
Open access Sep 2026

Gut microbiota variation in admixed Hispanic populations with polyendocrine metabolic ovarian syndrome

It is suggested that PMOS is not characterized by major gut microbiome shifts but may involve subtle depletion of health-associated commensals and increased microbial heterogeneity.

Loida A. González-Rodríguez, Keishla M. Jimenez-Ortega, D. Vargas-Robles et al. · 0 citations
Aug 2026

Environmental Endocrine Disruptors Activate CBX2 to Disrupt Cholesterol Homeostasis in PCOS.

A novel EDC-CBX2-H3K27me3 epigenetic axis that decouples GC proliferation from metabolic support functions is revealed, establishing CBX2 as both a molecular biomarker and potential therapeutic target for environment-associated PCOS.

Chan Zhu, Xian-Liang Qiu, Hong Yang et al. · 0 citations
Review Open access Jul 2026

Role of Ovarian Development Genes in the Pathogenesis of Polycystic Ovary Syndrome

A narrative review synthesizes evidence at the intersection of developmental biology, genomic architecture, and epigenetics to delineate how dysregulated ovarian developmental pathways contribute to PCOS pathogenesis.

Ayşegül Karahanoğlu, M. Ozer, Y. Terzi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.